Similar Intrapatient Blood Glucose Variability with LY2963016 and Lantus® Insulin Glargine in Patients with Type 1 (T1D) or Type 2 Diabetes, Including a Japanese T1D Subpopulation

被引：0
|
作者：
Hiroshi Nishiyama
Tomotaka Shingaki
Yumi Suzuki
Liza L. Ilag
机构：
[1] Eli Lilly Japan,
[2] K.K.,undefined
[3] Eli Lilly and Company,undefined
来源：
Diabetes Therapy | 2018年 / 9卷
关键词：
Blood glucose variability; Insulin glargine; Japanese subgroup; LY2963016; Type 1 diabetes; Type 2 diabetes;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1469 / 1476
页数：7
相关论文
共 50 条
  • [1] Similar Intrapatient Blood Glucose Variability with LY2963016 and LantusA® Insulin Glargine in Patients with Type 1 (T1D) or Type 2 Diabetes, Including a Japanese T1D Subpopulation
    Nishiyama, Hiroshi
    Shingaki, Tomotaka
    Suzuki, Yumi
    Ilag, Liza L.
    [J]. DIABETES THERAPY, 2018, 9 (04) : 1469 - 1476
  • [2] Immunogenicity of LY2963016 insulin glargine and Lantus® insulin glargine in Chinese patients with type 1 or type 2 diabetes mellitus
    Wang, Weimin
    Song, Xiang
    Lou, Ying
    Du, Liying
    Zhu, Dalong
    Zhou, Zhiguang
    [J]. DIABETES OBESITY & METABOLISM, 2022, 24 (06): : 1094 - 1104
  • [3] Evaluation of immunogenicity of LY2963016 insulin glargine compared with Lantus® insulin glargine in patients with type 1 or type 2 diabetes mellitus
    Ilag, L. L.
    Deeg, M. A.
    Costigan, T.
    Hollander, P.
    Blevins, T. C.
    Edelman, S. V.
    Konrad, R. J.
    Ortmann, R. A.
    Pollom, R. K.
    Huster, W. J.
    Zielonka, J. S.
    Prince, M. J.
    [J]. DIABETES OBESITY & METABOLISM, 2016, 18 (02): : 159 - 168
  • [4] LY2963016 Insulin Glargine: A Review in Type 1 and 2 Diabetes
    Lamb, Yvette N.
    Syed, Yahiya Y.
    [J]. BIODRUGS, 2018, 32 (01) : 91 - 98
  • [5] LY2963016 Insulin Glargine: A Review in Type 1 and 2 Diabetes
    Yvette N. Lamb
    Yahiya Y. Syed
    [J]. BioDrugs, 2018, 32 : 91 - 98
  • [6] Efficacy and Safety of MK-1293 Insulin Glargine Compared with Originator Insulin Glargine (Lantus) in Type 1 Diabetes (T1D)
    Home, Philip
    Golm, Gregory
    Carofano, Wendy
    Eldor, Roy
    Crutchlow, Michael
    Marcos, Michael
    Rosenstock, Julio
    Hollander, Priscilla
    Gallwitz, Baptist
    [J]. DIABETES, 2016, 65 : A78 - A78
  • [7] Similar Efficacy and Safety with LY2963016 Insulin Glargine Compared with Lantus® Insulin Glargine in Patients with T1DM: The ELEMENT 1 Study
    Blevins, Thomas
    Dahl, Dominik
    Rosenstock, Julio
    Ilag, Liza
    Huster, William J.
    Pollom, Robyn K.
    Prince, Melvin J.
    [J]. DIABETES, 2014, 63 : A19 - A19
  • [8] Comparative Pharmacokinetics (PK) and Pharmacodynamics (PD) of a Proposed Biosimilar Insulin Glargine and Lantus® in Patients with Type 1 Diabetes (T1D)
    Heise, Tim
    Tagore, Ranitendranath
    Donnelly, Charles
    Barve, Abhijit
    Jacob, Anand
    [J]. DIABETES, 2017, 66 : A268 - A268
  • [9] Correction to: LY2963016 Insulin Glargine: A Review in Type 1 and 2 Diabetes
    Yvette N. Lamb
    Yahiya Y. Syed
    [J]. BioDrugs, 2018, 32 : 181 - 181
  • [10] Comment on: LY2963016 Insulin Glargine: A Review in Type 1 and 2 Diabetes
    Riccardo Perfetti
    [J]. BioDrugs, 2018, 32 : 177 - 177
12345